X 4 Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on August 2, 2010. The company is a late-stage clinical-stage biopharmaceutical company that discovers and develops new therapies for the treatment of rare diseases and diseases with limited treatment options, focusing on diseases caused by immune system dysfunction. The company's lead clinical candidate is mavorixafor, a small molecule selective antagonist of the chemokine receptor CXCR4, which is being developed as an oral, once-daily therapy. Because mavorixafor can increase the mobilization of mature, functional white blood cells into the bloodstream, the company believes that mavorixafor has the potential to provide therapeutic benefits in a variety of chronic neutropenia, including WHIM (warts, hypogammaglobulinemia, infection and myelochalasia) syndrome, a rare primary immunodeficiency.
